Corvus Pharma Com (CRVS) Stock Price, Quote & News

Company Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psori...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 900 4520

Website: www.corvuspharma.com

Address:

901 Gateway Boulevard, Third Floor, South San Francisco, United States

tradingjunk321 Feb. 7 at 1:40 PM

$CRVS Full steam ahead folks! Corvus now has 6 job postings on their website, that's 3 new positions in the last week! Good thing they moved their headquarters to 901 Gateway Blvd. When they get to big they can move across the street to Pfizer, Abbvie or Amgen 😂. I like the new job posting "Director, drug product development and manufacturing" sounds promising! Moore to come folks!

0 · Reply

Bullchart Feb. 7 at 12:05 PM

$CRVS It will happen... only a matter of time. Next couple weeks should take care of most of it.

1 · Reply

lousjamsession Feb. 7 at 5:49 AM

$CRVS

0 · Reply

BesTrades1 Feb. 6 at 10:49 PM

$CRVS Expecting $15 by next Friday.

1 · Reply

tradingjunk321 Feb. 6 at 9:59 PM

$CRVS 😂 I've been blocking all Shorts and idiots like KingTut. I'd be so scared what is to come! Moore to come!

1 · Reply

Clearly1234 Feb. 6 at 7:43 PM

$CRVS make your arguments in court. Nobody cares on stock*****

1 · Reply

fubar444 Feb. 6 at 7:30 PM

$CRVS please post your legal correspondence with the offices for Jefferies, Goldman Sachs, Mizuho, Landenburg Thalmann and the 6100 longs who have been on this board before 1.15.2026. very

0 · Reply

hzhou088 Feb. 6 at 7:19 PM

$CRVS

2 · Reply

702mrcool Feb. 6 at 7:06 PM

$CRVS fill that in

1 · Reply

Clearly1234 Feb. 6 at 6:44 PM

$CRVS just saw some more people from this company getting booked for prison. omg.

1 · Reply

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Jan 21, 2026, 10:53 PM EST - 16 days ago

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Jan 21, 2026, 2:50 PM EST - 16 days ago

Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon

Jan 21, 2026, 11:43 AM EST - 16 days ago

Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know

Jan 20, 2026, 5:15 PM EST - 17 days ago

Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript

Jan 20, 2026, 4:01 PM EST - 17 days ago

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 20, 2026, 2:10 PM EST - 17 days ago

What made Corvus stock double on Tuesday and is it sustainable?

Jan 20, 2026, 2:00 PM EST - 17 days ago

Corvus Stock Spikes On Heels Of Strong Eczema Study Results

Jan 16, 2026, 4:01 PM EST - 21 days ago

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Nov 4, 2025, 7:16 PM EST - 3 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:01 PM EST - 3 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Oct 31, 2025, 7:30 AM EDT - 3 months ago

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 28, 2025, 4:01 PM EDT - 3 months ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Oct 17, 2025, 10:00 AM EDT - 4 months ago

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Oct 2, 2025, 4:01 PM EDT - 4 months ago

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Aug 12, 2025, 11:31 PM EDT - 6 months ago

Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts

Aug 8, 2025, 3:20 PM EDT - 6 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:01 PM EDT - 6 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Jun 4, 2025, 7:00 AM EDT - 8 months ago

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

May 28, 2025, 4:01 PM EDT - 9 months ago

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 9, 2025, 11:57 AM EDT - 9 months ago

Why Is Corvus Pharmaceuticals Stock Soaring On Friday?

May 8, 2025, 11:06 PM EDT - 9 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:02 PM EDT - 9 months ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 9 months ago

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Apr 23, 2025, 4:08 PM EDT - 10 months ago

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Apr 9, 2025, 4:01 PM EDT - 10 months ago

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Mar 28, 2025, 9:30 AM EDT - 11 months ago

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials

Mar 28, 2025, 9:29 AM EDT - 11 months ago

Corvus Pharmaceuticals: Now At Cruising Altitude

Mar 25, 2025, 7:58 PM EDT - 11 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 4:01 PM EDT - 11 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 20, 2025, 8:00 AM EDT - 11 months ago

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Mar 19, 2025, 4:01 PM EDT - 11 months ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 17, 2025, 4:01 PM EDT - 11 months ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Mar 12, 2025, 8:00 AM EDT - 11 months ago

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Feb 4, 2025, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 13, 2025, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 7, 2025, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 1:36 PM EST - 1 year ago

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting

Dec 18, 2024, 1:23 PM EST - 1 year ago

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Dec 18, 2024, 8:42 AM EST - 1 year ago

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

HEI TSLA

Dec 18, 2024, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Dec 17, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Dec 4, 2024, 4:05 PM EST - 1 year ago

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Nov 14, 2024, 10:01 AM EST - 1 year ago

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Nov 13, 2024, 1:18 PM EST - 1 year ago

Corvus Pharmaceuticals: The Market Likes The Story

Nov 13, 2024, 12:02 AM EST - 1 year ago

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 9, 2024, 1:40 PM EST - 1 year ago

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Nov 5, 2024, 4:02 PM EST - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

tradingjunk321 Feb. 7 at 1:40 PM

0 · Reply

Bullchart Feb. 7 at 12:05 PM

$CRVS It will happen... only a matter of time. Next couple weeks should take care of most of it.

1 · Reply

lousjamsession Feb. 7 at 5:49 AM

$CRVS

0 · Reply

BesTrades1 Feb. 6 at 10:49 PM

$CRVS Expecting $15 by next Friday.

1 · Reply

tradingjunk321 Feb. 6 at 9:59 PM

$CRVS 😂 I've been blocking all Shorts and idiots like KingTut. I'd be so scared what is to come! Moore to come!

1 · Reply

Clearly1234 Feb. 6 at 7:43 PM

$CRVS make your arguments in court. Nobody cares on stock*****

1 · Reply

fubar444 Feb. 6 at 7:30 PM

$CRVS please post your legal correspondence with the offices for Jefferies, Goldman Sachs, Mizuho, Landenburg Thalmann and the 6100 longs who have been on this board before 1.15.2026. very

0 · Reply

hzhou088 Feb. 6 at 7:19 PM

$CRVS

2 · Reply

702mrcool Feb. 6 at 7:06 PM

$CRVS fill that in

1 · Reply

Clearly1234 Feb. 6 at 6:44 PM

$CRVS just saw some more people from this company getting booked for prison. omg.

1 · Reply

Clearly1234 Feb. 6 at 6:11 PM

$CRVS I will sue people who break the law until the day I die because of this trashy stock.

1 · Reply

hzhou088 Feb. 6 at 6:10 PM

$CRVS

1 · Reply

Clearly1234 Feb. 6 at 5:49 PM

$CRVS trashy criminal stock. omg.

1 · Reply

VISIUM Feb. 6 at 3:46 PM

$CRVS shorts who want the gap filled are going to get their gap filled.

1 · Reply

fubar444 Feb. 6 at 2:02 PM

$CRVS What's the short thesis? @TimeTaEat Do you think that was institutional or retail buying 400k shares (1/3 of the daily volume) in the last 10 minutes of the trading day yesterday?

3 · Reply

TimeTaEat Feb. 6 at 1:44 PM

$CRVS

1 · Reply

mingdalee1982 Feb. 6 at 8:42 AM

$CRVS Primary Completion (Estimated)-2026-03-01. Maybe initial results?

3 · Reply

Semiraz Feb. 6 at 4:18 AM

$CRVS finally going back to $15 than $10

2 · Reply

BillionerOfKing Feb. 6 at 4:11 AM

$CRVS Current Stock Price: $19.03 Contracts to trade: $19.0 CRVS Feb 20 2026 Call Entry: $1.15 Exit: $1.56 ROI: 36% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

fubar444 Feb. 6 at 12:12 AM

$CRVS Bullish results from TERA and PLTR were crushed. Stock market pummelled. Crypto falling. The thesis here is unchanged. Generational wealth building opportunity. Institutions are accumulating algorithmically and in multi-decimal point increments. ALPS 2 in March will be positive. Accumulate in increments along with them. Anything below $22 is a steal . Very

2 · Reply

TimeTaEat Feb. 5 at 11:40 PM

$CRVS I won’t be surprised if this pumps tomorrow or Monday

1 · Reply

702mrcool Feb. 5 at 10:36 PM

$CRVS it on the right direction $10 in two weeks

1 · Reply

Market Cap	1.60B
Revenue (ttm)	0.00
Net Income (ttm)	-62.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,708,100
Avg Vol	4,036,658
Day's Range	N/A - N/A
Shares Out	83.77M
Stochastic %K	34%
Beta	0.73
Analysts	Strong Sell
Price Target	$35.00